The efficacy and safety of QL1101 is compared to bevacizumab in the study led by Prof. Baohui Han. The study details are published in iCancer Biology (and) Medicine/i.
According to Prof. Han, "We're hopeful that QL1101 will reduce the therapeutic cost burden for patients with NSCLC."
In 2018, lung cancer caused 1.8 million cancer deaths worldwide. It is the most common type of cancer, with non-small cell lung cancers (NSCLCs) accounting for 85% of lung cancers.
Most recent lung cancer research ...
The efficacy and safety of QL1101 is compared to bevacizumab in the study led by Prof. Baohui Han. The study details are published in iCancer Biology (and) Medicine/i.
According to Prof. Han, "We're hopeful that QL1101 will reduce the therapeutic cost burden for patients with NSCLC."
In 2018, lung cancer caused 1.8 million cancer deaths worldwide. It is the most common type of cancer, with non-small cell lung cancers (NSCLCs) accounting for 85% of lung cancers.
Most recent lung cancer research ...